Mice with Very Low Expression of the Vesicular Monoamine Transporter 2 Gene Survive into Adulthood: Potential Mouse Model for Parkinsonism

REFERENCES

• Bergman, H., A. Feingold, A. Nini, A. Raz, H. Slovin, M. Abeles, and E. Vaadia. 1998. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci. 21:32–38.
   PubMed Web of Science ®Google Scholar
• Bergman, H., T. Wichmann, and M. R. DeLong. 1990. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436–1438.
   PubMed Web of Science ®Google Scholar
• Björklund, A., and O. Lindvall. 1975. Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res. 83:531–537.
   PubMed Web of Science ®Google Scholar
• Chase, T. N., J. D. Oh, and P. J. Blanchet. 1998. Neostriatal mechanisms in Parkinson's disease. Neurology 51:30–35.
   Google Scholar
• Dahlström, A., and K. Fuxe. 1964. Evidence for the existence of monoamine-containing neurons in the central nervous system. 1. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. Suppl. 62:232
   Google Scholar
• Egan, M. F., and D. R. Weinberger. 1997. Neurobiology of schizophrenia. Curr. Opin. Neurobiol. 7:701–707.
   PubMed Web of Science ®Google Scholar
• Erickson, J. D., L. E. Eiden, and B. J. Hoffman. 1992. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 89:10993–10997.
   PubMed Web of Science ®Google Scholar
• Fernandez, A., M. L. de Ceballos, S. Rose, P. Jenner, and C. D. Marsden. 1996. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain 119:823–830.
   PubMedGoogle Scholar
• Fon, E. A., E. N. Pothos, B.-C. Sun, N. Killeen, D. Sulzer, and R. H. Edwards. 1997. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19:1271–1283.
   PubMedGoogle Scholar
• Forrest, D., M. Yuzaki, H. D. Soares, L. Ng, D. C. Luk, M. Sheng, C. L. Stewart, J. I. Morgan, J. A. Connor, and T. Curran. 1994. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 13:325–338.
   PubMed Web of Science ®Google Scholar
• Gerfen, C. H.. 1992. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15:285–320.
   PubMed Web of Science ®Google Scholar
• Guevara-Guzman, R., P. C. Emson, and K. M. Kendrick. 1994. Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J. Neurochem. 62:807–810.
   PubMed Web of Science ®Google Scholar
• Herrero, M. T., S. J. Augood, E. C. Hirsch, F. Javoy-Agid, M. R. Luquin, Y. Agid, J. A. Obeso, and P. C. Emson. 1995. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68:1189–1198.
   PubMedGoogle Scholar
• Hornykiewicz, O.. 1966. Metabolism of brain dopamine in human parkinsonism: neurochemical and clinical aspects. Biochemistry and Pharmacology of the basal ganglia.. X. Costa, L. J. Côté, and M. D. Yahr. 171–185. Raven Press, New York, N.Y
   Google Scholar
• Jolkkonen, J., P. Jenner, and C. D. Marsden. 1995. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol. Brain Res. 32:297–307.
   PubMedGoogle Scholar
• Koob, G. F., and M. Le Moal. 1997. Drug abuse and alcoholism. Overview. Science 278:52–58.
   PubMed Web of Science ®Google Scholar
• Levy, R., L. N. Hazrati, M. T. Herrero, M. Vila, O. K. Hassani, M. Mouroux, M. Ruberg, H. Asensi, Y. Agid, J. Feger, J. A. Obeso, A. Parent, and E. C. Hirsch. 1997. Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. Neuroscience 76:335–343.
   PubMedGoogle Scholar
• Liu, Y., and R. H. Edwards. 1997. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20:125–156.
   PubMed Web of Science ®Google Scholar
• Liu, Y., D. Peter, A. Roghani, S. Schuldiner, G. G. Prive, D. Eisenberg, N. Brecha, and R. H. Edwards. 1992. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70:539–551.
   PubMed Web of Science ®Google Scholar
• Liu, Y., R. S. Erzurumlu, C. Chen, S. Jhaveri, and S. Tonegawa. 1994. Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell 76:427–437.
   PubMedGoogle Scholar
• Mansour, S. L., K. R. Thomas, and M. R. Capecchi. 1988. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 336:348–352.
   PubMed Web of Science ®Google Scholar
• Melton, D. W., D. S. Konecki, J. Brennand, and C. T. Caskey. 1984. Structure, expression, and mutation of the hypoxanthinephosphoribosyltransferase gene. Proc. Natl. Acad. Sci. USA 81:2147–2151.
   PubMed Web of Science ®Google Scholar
• Mittleman, G., H. J. Jones, and T. W. Robbins. 1991. Sensitisation of amphetamine-stereotypy reduces plasma corticosterone: implications for stereotypy as a coping response. Behav. Neural Biol. 56:170–182.
   PubMedGoogle Scholar
• Mohn, A. R., R. R. Gainetdinov, M. G. Caron, and B. H. Koller. 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427–436.
   PubMed Web of Science ®Google Scholar
• Moore, R. Y., and F. E. Bloom. 1979. Central catecholamine system: anatomy and physiology of norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 2:113–168.
   PubMed Web of Science ®Google Scholar
• Nestler, E. J., and G. K. Aghajanian. 1997. Molecular and cellular basis of addiction. Science 278:58–63.
   PubMed Web of Science ®Google Scholar
• Nieuwboer, A., W. De Weerdt, R. Dom, and E. Lesaffre. 1998. A frequency and correlation analysis of motor deficits in Parkinson patients. Disabil. Rehabil. 20:142–150.
   PubMed Web of Science ®Google Scholar
• Peter, D., Y. Liu, C. Sternini, R. de Giorgio, N. Brecha, and R. H. Edwards. 1995. Differential expression of two vesicular monoamine transporters. J. Neurosci. 15:6179–6188.
   PubMed Web of Science ®Google Scholar
• Plagge, A., G. Kelsey, and N. D. Allen. 1999. Directed mutagenesis in embryonic stem cells. Mouse genetics and transgenics.. I. J. Jackson, and C. M. Abbott. 247–284. Oxford University Press, Oxford, United Kingdom
   Google Scholar
• Robbins, T. W., G. Mittleman, J. O'Brien, and P. Winn. 1990. The neuropsychological significance of stereotypy induced by stimulant drugs. Neurobiology of stereotyped behaviour.. S. J. Cooper, and C. T. Dourish. 25–63. Oxford University Press, Claredon, United Kingdom
   Google Scholar
• Schlomo, B.. 1997. The epidemiology of Parkinson's disease. Baillieres Text. Clin. Neurol. 6:55–68.
   PubMedGoogle Scholar
• Seeman, P., C. Ulpian, C. Bergeron, P. Riederer, K. Jellinger, E. Gabriel, G. P. Reynolds, and W. W. Tourtellotte. 1984. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225:728–731.
   PubMed Web of Science ®Google Scholar
• Takahashi, N., and G. Uhl. 1997. Murine vesicular monoamine transporter 2: molecular cloning and genomic structure. Mol. Brain Res. 49:7–14.
   PubMedGoogle Scholar
• Takahashi, N., L. L. Miner, I. Sora, H. Ujike, R. S. Revay, V. Kostic, V. Jackson-Lewis, S. Przedborski, and G. R. Uhl. 1997. VMAT2 knockout mice: heterozygotes display reduced amphetamine conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA 94:9938–9943.
   PubMedGoogle Scholar
• Uhl, G. R.. 1998. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann. Neurol. 43:555–560.
   PubMed Web of Science ®Google Scholar
• Wang, Y.-M., R. R. Gainetdinov, F. Fumagalli, F. Xu, S. R. Jones, C. B. Bock, G. W. Miller, R. M. Wightman, and M. G. Caron. 1997. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19:1285–1296.
   PubMedGoogle Scholar
• Young, W. S., T. I. Bonner, and M. R. Brann. 1986. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA 83:9827–9831.
   PubMedGoogle Scholar